Recovery after ICU stay with Akkermansia supplement
Part of Infections clinical trials.
This trial tests if taking a specific bacteria called Akkermansia muciniphila can help you recover faster after being in the ICU with sepsis. The supplement aims to support gut health and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were in the ICU for at least 2 days with a diagnosis of sepsis
- You received a specific antibiotic (SDD or a cephalosporin) during your ICU stay
- You are now recovering on a regular hospital ward
- You are able to give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria affect severe infections in the ICU. It tests whether the microbiome can be a source of sepsis and a target for treatment. If you are critically ill or a long-term sepsis survivor, you might help find new ways to prevent infections.
This study looks at how your immune system and inflammation affect your recovery in the intensive care unit. Researchers want to understand why some patients do better than others.
This trial looks at natural molecules that help the body resolve severe infections. Researchers want to understand how these molecules affect recovery and identify patient types that respond best. It may help improve treatment for people in the ICU with serious infections.
This trial tests if giving antibiotics based on a patient's unique gut bacteria can prevent pneumonia in people who are on a breathing machine (ventilator) in the intensive care unit (ICU). It aims to see if this personalized approach is more effective than standard care.
This trial tests if a fecal microbiota transplant (FMT) can improve survival and recovery in ICU patients with sepsis. FMT involves transferring healthy donor bacteria into your gut to help fight severe infection.
This trial tests whether adding L-citrulline to tube feeding (enteral nutrition) can improve outcomes for people in the ICU with sepsis or septic shock. It may help support the body’s immune response while you’re critically ill.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.